Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Stock Short Interest Report for September

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 56,600 shares, a decrease of 52.6% from the September 15th total of 119,360 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 121,092 shares, the short-interest ratio is presently 0.5 days.

Analysts Set New Price Targets

Separately, BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Serina Therapeutics in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.00.

Serina Therapeutics Stock Performance

Shares of NYSEAMERICAN:SER traded down $0.11 on Wednesday, reaching $1.71. 41,258 shares of the company’s stock were exchanged, compared to its average volume of 1,488,652. Serina Therapeutics has a twelve month low of $1.22 and a twelve month high of $5.29. The company has a fifty day moving average of $2.39 and a 200-day moving average of $2.10. The company has a market capitalization of $43.43 million, a price-to-earnings ratio of -0.90 and a beta of 1.19. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) EPS for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines designed to provide controlled and sustained drug delivery. The company’s proprietary POZ polymer platform is intended to extend the duration of action of therapeutic compounds, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apomorphine, an investigational long-acting formulation of apomorphine being developed for patients with Parkinson’s disease.